Alumis said on Tuesday its experimental drug met the main goal of improving symptoms of a common skin disease in two late-stage studies, powering its shares to a record high and more than doubling ...

Oregon Medical Research Center in Portland, Oregon, has led a phase 2 trial in moderate-to-severe plaque psoriasis that ...

Alumis Inc. surged on Phase 3 psoriasis data for envudeucitinib. Click for this look at ALMS stock and why I am bullish on ...

Psoriasis affecting the hands and feet can be difficult to distinguish clinically from eczema. Unfortunately, a biopsy of an area thought to be volar psoriasis is of little diagnostic value, as it is ...

Psoriasis causes your body to make new skin cells too quickly. These cells tend to pile up and form spots, bumps, and thick scaly patches called plaques that can be uncomfortable. Scientists think ...

Psoriasis is a chronic skin disease where red, scaly, itchy patches break out all over your body. It’s an autoimmune disease in which your immune system goes haywire and triggers inflammation of your ...